Preclinical study demonstrates that blocking RhoA-driven secretory autophagy in megakaryocytes alleviates myelofibrosis in mice, indicating a potential target for antifibrotic therapies.
TGFβ1 is released from megakaryocytes via RhoA-mediated secretory autophagy, and targeting this process can alleviate fibrosis progression in a preclinical mouse model of myelofibrosis.
No takes yet. Share an insight, caveat, or question.
Becker et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: